|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor.
|
31460428 |
2019 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that mannosylated Trp-2 and MPLA-loaded PBAE nano-vaccines can target and mature DCs, consequently boosting antigen-specific cytotoxic T lymphocyte activity against melanoma.
|
31593795 |
2019 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunization with melanoma antigens conjugated to antibodies (Abs) specific for mouse CD169 efficiently induced gp100 and Trp2-specific T cell responses in mice.
|
30764534 |
2019 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
LCP mRNA vaccine encoding TRP2 elicited a robust antigen-specific cytotoxic T cell response and a humoral immune response in a C57BL/6 mouse model of B16F10 melanoma.
|
29249397 |
2018 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8<sup>+</sup> T cells in the tumor microenvironment can be significantly enhanced.
|
30005865 |
2018 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
|
29355622 |
2018 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
|
29296525 |
2017 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously developed a potent mannose-modified lipid calcium phosphate (LCP) nanoparticle (NP)-based Trp2 vaccine for melanoma therapy, but because this vaccine can induce a potent anti-tumor immune response only during the early stages of melanoma, poor tumor growth inhibition has been observed in more advanced melanoma models, likely due to the development of an immune-suppressive tumor microenvironment (TME).
|
27863995 |
2017 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice.
|
28273716 |
2017 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLA individually or mixed with uncharged glyolipid (lactosylarchaeol, LA) constituted efficacious carrier vesicles for entrapped antigens (ovalbumin or melanoma associated tyrosinase-related protein 2 [TRP-2]) and induction of strong cell-mediated responses in mice and protection against subsequent B16 melanoma tumor challenge.
|
28537465 |
2017 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
p53 regulation by TRP2 is not pervasive in melanoma.
|
24475287 |
2014 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human SmartDC-TRP2 generated with monocytes obtained from melanoma patients secreted endogenous cytokines associated with DC activation and stimulated TRP2-specific autologous T-cell expansion in vitro.
|
22428979 |
2012 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
|
20844763 |
2010 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
To scan the human melanoma differentiation antigens TRP-1 and TRP-2 for HLA-DRB1*0301-restricted CD4+ T cell epitopes we applied the following methodology: Splenocytes of HLA-DRB1*0301-transgenic mice immunized with recombinant adenovirus encoding TRP-1 (Ad5.TRP-1) or TRP-2 (Ad5.TRP-2) were tested for their T cell reactivity against combinatorial TRP-1- and TRP-2-specific peptide libraries.
|
21152437 |
2010 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the addition of ABT-737 to either a vaccine strategy involving priming with TRP-2 melanoma antigen peptide-pulsed DC and boosting with recombinant Listeria monocytogenes expressing the same melanoma antigen, or the adoptive transfer of TCR transgenic cells, did not result in superior antitumor activity against B16 murine melanoma.
|
18807035 |
2009 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRP-2 epitope was detected by IHC in 20/24 primary melanomas (83%), 9/9 metastatic melanomas (100%) and 4/6 nevi (67%).
|
18204435 |
2008 |
|
TRP-AGG2-6
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
C57Bl/6J mice were injected subcutaneously with bone marrow derived dendritic cells (DCs) pulsed with a melanoma epitope (TRP2-P2/Agonist), melanoma epitope tyrosinase (TYR/Agonist), a nonfunctional reverse conformation C5a agonist bound to TYR(reverse peptide) or DMSO-PBS vehicle.
|
17986862 |
2007 |
|
TRP-AGG2-6
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immunization with melanoma-associated antigens was accomplished using recombinant adenovirus (Ad) vectors encoding human gp100 (Ad2/gp100) or murine TRP-2 (Ad2/mTRP-2).
|
15235388 |
2005 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We focused on three known differentiation MAAs: tyrosinase (TYR), TYR-related protein 2 (TRP-2), and melanoma antigen recognized by T cells 1 (MART-1); all three of them are known to induce immune responses in melanoma patients and are frequently expressed in melanomas.
|
12543800 |
2003 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The melanosomal protein TRP2 expressed by melanocytes and most melanoma cells is an attractive, clinically relevant model antigen for the experimental development of melanoma immunotherapy in mice.
|
10728600 |
2000 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, proteasome inhibitors preventing the generation of the MART-1/Melan-A(27-35) immunodominant melanoma tumor-associated antigen (TAA) promoted detectable presentation of TRP-2(476-484) epitope in HLA-A2.1(+) and TRP-2(+) tumor lines, as witnessed by cytokine release by specific T-cell clones.
|
10861482 |
2000 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that peripheral T cell tolerance toward murine melanoma self-antigens gp100 and TRP-2 can be broken by an autologous oral DNA vaccine containing the murine ubiquitin gene fused to minigenes encoding peptide epitopes gp100(25-33) and TRP-2(181-188).
|
10779556 |
2000 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis.
|
10596909 |
1999 |
|
TRP-AGG2-6
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRP-2 antibody responses provide a linkage between autoimmune responses by vitiligo patients and melanoma patients responding to immunotherapy who have induced hypopigmentation.
|
9856813 |
1998 |
|
TRP-AGG2-6
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative reverse transcription PCR analysis carried out on total and/or cytoplasmic mRNA demonstrated that, in contrast to the fully spliced TRP-2 mRNA expressed in melanomas, normal skin melanocytes, and retina, the TRP-2-INT2 mRNA could be detected at significant levels in melanomas but not in normal cells of the melanocytic lineage.
|
9743519 |
1998 |